PL2291659T3 - Małe cząsteczki chimerowe do rekrutacji przeciwciał do komórek nowotworowych - Google Patents

Małe cząsteczki chimerowe do rekrutacji przeciwciał do komórek nowotworowych

Info

Publication number
PL2291659T3
PL2291659T3 PL09746950T PL09746950T PL2291659T3 PL 2291659 T3 PL2291659 T3 PL 2291659T3 PL 09746950 T PL09746950 T PL 09746950T PL 09746950 T PL09746950 T PL 09746950T PL 2291659 T3 PL2291659 T3 PL 2291659T3
Authority
PL
Poland
Prior art keywords
recruitment
antibodies
cancer cells
small molecules
chimeric small
Prior art date
Application number
PL09746950T
Other languages
English (en)
Inventor
David Spiegel
Ryan Murelli
Andrew Zhang
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of PL2291659T3 publication Critical patent/PL2291659T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL09746950T 2008-05-13 2009-05-13 Małe cząsteczki chimerowe do rekrutacji przeciwciał do komórek nowotworowych PL2291659T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12753908P 2008-05-13 2008-05-13
EP09746950.6A EP2291659B1 (en) 2008-05-13 2009-05-13 Chimeric small molecules for the recruitment of antibodies to cancer cells
PCT/US2009/002957 WO2009139863A2 (en) 2008-05-13 2009-05-13 Chimeric small molecules for the recruitment of antibodies to cancer cells

Publications (1)

Publication Number Publication Date
PL2291659T3 true PL2291659T3 (pl) 2016-04-29

Family

ID=41319210

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09746950T PL2291659T3 (pl) 2008-05-13 2009-05-13 Małe cząsteczki chimerowe do rekrutacji przeciwciał do komórek nowotworowych

Country Status (14)

Country Link
US (1) US8859509B2 (pl)
EP (1) EP2291659B1 (pl)
JP (1) JP5746615B2 (pl)
CA (1) CA2723816C (pl)
CY (1) CY1118408T1 (pl)
DK (1) DK2291659T3 (pl)
ES (1) ES2556629T3 (pl)
HR (1) HRP20151367T1 (pl)
HU (1) HUE025618T2 (pl)
PL (1) PL2291659T3 (pl)
PT (1) PT2291659E (pl)
RS (1) RS54428B1 (pl)
SI (1) SI2291659T1 (pl)
WO (1) WO2009139863A2 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873982A (zh) 2007-08-17 2015-09-02 普渡研究基金会 Psma结合配体-接头缀合物及其使用方法
US8852630B2 (en) * 2008-05-13 2014-10-07 Yale University Chimeric small molecules for the recruitment of antibodies to cancer cells
WO2010093706A2 (en) * 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
AU2011329829B2 (en) 2010-11-18 2017-02-09 Yale University Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
US20140308342A1 (en) 2011-11-11 2014-10-16 Yale University Reprogramming urokinase into an antibody-recruiting anticancer agent
ES2905359T3 (es) 2012-04-26 2022-04-08 Univ Yale Moléculas de suministro de fármacos citotóxicos dirigidas al VIH (CDM-H), actividad citotóxica contra el virus de la inmunodeficiencia humana y métodos de uso
WO2013166110A1 (en) 2012-05-02 2013-11-07 Yale University Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
MX363787B (es) * 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
EP2970505A4 (en) 2013-03-14 2016-10-19 California Inst Biomedical Res SPECIFIC ANTIBODIES AND USES THEREOF
JP6473138B2 (ja) * 2013-05-03 2019-02-20 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 癌、特に前立腺癌を標的とする合成抗体模倣化合物（ＳｙＡＭ）
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
AU2014384434B2 (en) 2014-02-28 2016-11-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
US20230159611A1 (en) * 2017-07-03 2023-05-25 Yale University Small molecule adapter regulated, target specific chimeric antigen receptor bearing t cells (smart cars)
EP3927330A4 (en) * 2019-02-19 2022-11-30 The Regents of the University of California NURR1 RECEPTOR MODULATORS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SK288201B6 (sk) * 2000-03-31 2014-06-03 Purdue Research Foundation Farmaceutický prostriedok
IL138825A (en) 2000-10-03 2006-06-11 Neurim Pharma 1991 Pharmaceutical preparations containing tryptamine derivatives and similar compounds, and such new compounds
WO2002043773A2 (en) * 2000-12-01 2002-06-06 The Johns Hopkins University Tissue specific prodrugs
DE60329274D1 (de) 2002-01-10 2009-10-29 Univ Johns Hopkins Kontrastmittel und verfahren zum imaging von naaldase oder psma
EP1708750A1 (en) 2003-11-28 2006-10-11 Mitra Medical AB Targeting of erb antigens
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
CN114053429A (zh) * 2004-06-01 2022-02-18 健泰科生物技术公司 抗体-药物偶联物和方法
WO2006015318A2 (en) 2004-07-30 2006-02-09 Biogen Idec Inc. Antibody conjugated to a drug moiety via a poptidic linker
CN101287498B (zh) 2005-06-20 2013-03-27 Psma开发有限公司 Psma抗体-药物缀合物
WO2007011339A1 (en) * 2005-07-14 2007-01-25 Voyager Pharmaceutical Corporation Methods for treating and preventing brain cancers
CN104873982A (zh) * 2007-08-17 2015-09-02 普渡研究基金会 Psma结合配体-接头缀合物及其使用方法

Also Published As

Publication number Publication date
PT2291659E (pt) 2016-01-22
ES2556629T3 (es) 2016-01-19
JP5746615B2 (ja) 2015-07-08
WO2009139863A3 (en) 2010-03-04
EP2291659B1 (en) 2015-09-16
DK2291659T3 (en) 2015-12-21
US20110201563A1 (en) 2011-08-18
SI2291659T1 (sl) 2016-02-29
JP2011523639A (ja) 2011-08-18
EP2291659A2 (en) 2011-03-09
CA2723816A1 (en) 2009-11-19
CA2723816C (en) 2017-06-20
US8859509B2 (en) 2014-10-14
RS54428B1 (en) 2016-04-28
WO2009139863A2 (en) 2009-11-19
CY1118408T1 (el) 2017-06-28
HUE025618T2 (en) 2016-04-28
HRP20151367T1 (hr) 2016-01-29
EP2291659A4 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
SI2291659T1 (sl) Himerične majhne molekule za pridobivanje protiteles za rakave celice
HUS1900007I1 (hu) Kiméra, antigénreceptor-módosított T-sejt alkalmazása rák kezelésére
HK1163134A1 (en) Antibodies to ccr2 ccr2
AP4039A (en) Boron-containing small molecules as antiprotozoal agents
IL211176A0 (en) Methods for the production of ips cells
EP3375462C0 (en) IMPROVEMENTS RELATING TO IMMOBILIZED BIOLOGICAL ENTITIES
HK1185887A1 (en) Improved antibody molecules
GB0903325D0 (en) Antibody molecules
HK1217711A1 (zh) 特異於鈣粘素- 的抗體
IL218163A0 (en) Boron-cotaining small molecules as antiprotozoal agents
EP2445513A4 (en) CHIMEROUS FACTOR VII MOLECULES
EP2331134A4 (en) ANTI-PANCREAS CANCER ANTIBODY
ZA201007751B (en) Novel antibodies used to treat cancer
EP2125890A4 (en) ANTIBODIES AGAINST PHOSPHORYLATED IRAQ4
EP2212431A4 (en) ANTI-IREM-1 ANTIBODIES
PT2488554T (pt) Anticorpos para epha3
GB201110726D0 (en) Improvements to immobilised biological entities